Fox Run Management L.L.C. Has $1.38 Million Stock Holdings in Haemonetics Corporation $HAE

Fox Run Management L.L.C. trimmed its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 38.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,151 shares of the medical instruments supplier’s stock after selling 10,710 shares during the period. Fox Run Management L.L.C.’s holdings in Haemonetics were worth $1,375,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. True Wealth Design LLC lifted its stake in Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 335 shares during the last quarter. Leonteq Securities AG acquired a new stake in Haemonetics in the 4th quarter valued at about $30,000. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in Haemonetics in the 4th quarter valued at about $40,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 837 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HAE has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and raised their target price for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Citigroup raised their target price on shares of Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, May 28th. JPMorgan Chase & Co. cut their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and an average price target of $77.11.

Haemonetics Stock Up 5.4%

Haemonetics stock opened at $75.15 on Tuesday. The stock has a market cap of $3.42 billion, a P/E ratio of 37.20, a P/E/G ratio of 1.43 and a beta of 0.55. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The company’s 50-day moving average price is $60.39 and its two-hundred day moving average price is $67.22.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. During the same period in the prior year, the firm earned $1.24 EPS. The business’s revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts expect that Haemonetics Corporation will post 5.23 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.